Japan's Astellas to Market New Immunosuppressive Drug Advagraf in Germany, UK (Japan)
This article was originally published in PharmAsia News
Japan's third largest pharmaceutical company Astellas Pharma will begin selling new immuno-suppressive product Advagraf for use during renal transplants in Germany and Britain on June 18. The company also is seeking Advagraf's approval in Japan and the United States. Astellas sells this once-per-day drug featuring tacrolimus as a way to treat symptoms of organ rejection in adult patients. Astellas' twice-per-day version, Prograf, is already used for liver and kidney transplant patients. (Click here for more
You may also be interested in...
Astellas Pharma received a second U.S. FDA "approvable" letter for use of its long-lasting immunosuppressant FK506 in kidney transplant patients, the company said March 14.
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.